Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 4955-4963, September 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gervasoni, J. E.
Right arrow Articles by Taub, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gervasoni, J. E., Jr.
Right arrow Articles by Taub, R. N.

Subcellular Distribution of Daunorubicin in P-Glycoprotein-positive and -negative Drug-resistant Cell Lines Using Laser-assisted Confocal Microscopy1

James E. Gervasoni, Jr., Scott Z. Fields, Sindu Krishna, Michael A. Baker, Michelle Rosado, Kalpna Thuraisamy, Alexander A. Hindenburg and Robert N. Taub2

Division of Medical Oncology, Department of Medicine, Columbia University, New York, New York 10032 [J. E. G., R. N. T., S. F., S. K., M. R.]; Winthrop University Hospital, Division of Oncology/Hematology, Mineola, New York 11501 [A. A. H.]; and Toronto General Hospital, Toronto, Ontario, Canada M5G 1L7 [M. A. B.]

Four well defined multidrug-resistant cell lines and their drug-sensitive counterparts were examined for intracellular distribution of daunorubicin (DNR) by laser-assisted confocal fluorescence microscopy: P-glycoprotein-negative HL-60/AR cells, and P-glycoprotein-positive P388/ADR, KBV-1, and MCF-7/ADR cells.

Both drug sensitive cell lines (HL-60/S, P388/S, KB3-1, and MCF-7/S) and drug-resistant cell lines (HL-60/AR, P388/ADR, KBV-1, and MCF-7/ADR) exposed to DNR showed a similar rapid distribution of drug from the plasma membrane to the perinuclear region within the first 2 min. From 2–10 min, the drug sensitive HL-60/S, P388/S, and MCF-7/S cells redistributed drug to the nucleus and to the cytoplasm in a diffuse pattern. In contrast, drug-resistant HL-60/AR, P388/ADR, and MCF-7/ADR redistributed DNR from the perinuclear region into vesicles distinct from nuclear structures, thereby assuming a "punctate" pattern. This latter redistribution could be inhibited by glucose deprivation (indicating energy dependence), or by lowering the temperature of the medium below 18°C. The differences in distribution between sensitive and resistant cells did not appear to be a function of intracellular DNR content, nor the result of drug cytotoxicity.

Drug-sensitive KB3-1 and -resistant KBV-1 cells did not fully follow this pattern in that they demonstrated an intracellular DNR distribution intermediate between HL-60/S and HL-60/AR cells with both "punctate" and nuclear/cytoplasmic uptake sometimes in the same cell. These data indicate that the intracellular distribution of DNR is an important determinant of drug resistance regardless of the overexpression of P-glycoprotein. The intracellular movement of drug requires the presence of glucose and a temperature above 18°C, implicating energy-dependent processes and vesicle fusion in the distribution process. This intracellular transport of DNR away from the nucleus in multidrug-resistant cells may protect putative cell targets such as DNA against drug toxicity.

1 Supported by Grants ACS CH-357, CA-31761, CA-42450, and CA-40188, and the William J. Matheson Foundation, the Medical Research Council of Canada, and the National Cancer Institute of Canada.

2 To whom requests for reprints should be addressed, at Columbia University Cancer Center, 630 168th Street, VC 12-213, New York, NY 10032.

Received 9/21/90. Accepted 7/ 9/91.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. van Zon, M. H. Mossink, M. Schoester, R. J. Scheper, P. Sonneveld, and E. A. C. Wiemer
Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression
Cancer Res., July 15, 2004; 64(14): 4887 - 4892.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T.-K. Li, P. J. Houghton, S. D. Desai, P. Daroui, A. A. Liu, E. S. Hars, A. L. Ruchelman, E. J. LaVoie, and L. F. Liu
Characterization of ARC-111 as a Novel Topoisomerase I-Targeting Anticancer Drug
Cancer Res., December 1, 2003; 63(23): 8400 - 8407.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Lansiaux, F. Tanious, Z. Mishal, L. Dassonneville, A. Kumar, C. E. Stephens, Q. Hu, W. D. Wilson, D. W. Boykin, and C. Bailly
Distribution of Furamidine Analogues in Tumor Cells: Targeting of the Nucleus or Mitochondria Depending on the Amidine Substitution
Cancer Res., December 15, 2002; 62(24): 7219 - 7229.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. B. Lichtner, A. Rotgeri, T. Bunte, B. Buchmann, J. Hoffmann, W. Schwede, W. Skuballa, and U. Klar
Subcellular distribution of epothilones in human tumor cells
PNAS, September 13, 2001; (2001) 171023398.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. A. Cabrita, T. C. Hobman, D. L. Hogue, K. M. King, and C. E. Cass
Mouse Transporter Protein, a Membrane Protein That Regulates Cellular Multidrug Resistance, Is Localized to Lysosomes
Cancer Res., October 1, 1999; 59(19): 4890 - 4897.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
N. Altan, Y. Chen, M. Schindler, and S. M. Simon
Defective Acidification in Human Breast Tumor Cells and Implications for Chemotherapy
J. Exp. Med., May 18, 1998; 187(10): 1583 - 1598.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
C. Millot, J.-M. Millot, H. Morjani, A. Desplaces, and M. Manfait
Characterization of Acidic Vesicles in Multidrug-resistant and Sensitive Cancer Cells by Acridine Orange Staining and Confocal Microspectrofluorometry
J. Histochem. Cytochem., September 1, 1997; 45(9): 1255 - 1264.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. J. Hurwitz, M. Terashima, N. Mizunuma, and C. A. Slapak
Vesicular Anthracycline Accumulation in Doxorubicin-Selected U-937 Cells: Participation of Lysosomes
Blood, May 15, 1997; 89(10): 3745 - 3754.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
S. Cole, G Bhardwaj, J. Gerlach, J. Mackie, C. Grant, K. Almquist, A. Stewart, E. Kurz, A. Duncan, and R. Deeley
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
Science, December 4, 1992; 258(5088): 1650 - 1654.
[Abstract] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. B. Lichtner, A. Rotgeri, T. Bunte, B. Buchmann, J. Hoffmann, W. Schwede, W. Skuballa, and U. Klar
Subcellular distribution of epothilones in human tumor cells
PNAS, September 25, 2001; 98(20): 11743 - 11748.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.